A citation-based method for searching scientific literature

Robert W Buchanan, Daniel C Javitt, Stephen R Marder, Nina R Schooler, James M Gold, Robert P McMahon, Uriel Heresco-Levy, William T Carpenter. Am J Psychiatry 2007
Times Cited: 296







List of co-cited articles
1528 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.
Donald C Goff, Corinne Cather, Jennifer D Gottlieb, A Eden Evins, Jared Walsh, Lisa Raeke, Michael W Otto, David Schoenfeld, Michael F Green. Schizophr Res 2008
95
23

The positive and negative syndrome scale (PANSS) for schizophrenia.
S R Kay, A Fiszbein, L A Opler. Schizophr Bull 1987
22

A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
Mark Weiser, Uriel Heresco-Levy, Michael Davidson, Daniel C Javitt, Nomi Werbeloff, Ari A Gershon, Yehuda Abramovich, Daniela Amital, Adiel Doron, Shai Konas,[...]. J Clin Psychiatry 2012
69
31

D-serine added to antipsychotics for the treatment of schizophrenia.
G Tsai, P Yang, L C Chung, N Lange, J T Coyle. Biol Psychiatry 1998
506
21

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
21

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
Daniel Umbricht, Daniela Alberati, Meret Martin-Facklam, Edilio Borroni, Eriene A Youssef, Michael Ostland, Tanya L Wallace, Frédéric Knoflach, Ernest Dorflinger, Joseph G Wettstein,[...]. JAMA Psychiatry 2014
141
20


d-Cycloserine augmentation of cognitive remediation in schizophrenia.
Christopher K Cain, Margaret McCue, Iruma Bello, Timothy Creedon, Dei-In Tang, Eugene Laska, Donald C Goff. Schizophr Res 2014
54
35

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
D C Goff, G Tsai, J Levitt, E Amico, D Manoach, D A Schoenfeld, D L Hayden, R McCarley, J T Coyle. Arch Gen Psychiatry 1999
310
18

Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Hsien-Yuan Lane, Ching-Hua Lin, Michael F Green, Gerhard Hellemann, Chih-Chia Huang, Po-Wei Chen, Rene Tun, Yue-Cung Chang, Guochuan E Tsai. JAMA Psychiatry 2013
136
18

Effects of D-cycloserine on negative symptoms in schizophrenia.
Erica J Duncan, Sandor Szilagyi, Marion P Schwartz, Dragana Bugarski-Kirola, Alena Kunzova, Shobhit Negi, Myrsini Stephanides, Toby R Efferen, Burt Angrist, Eric Peselow,[...]. Schizophr Res 2004
73
23

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
U Heresco-Levy, D C Javitt, M Ermilov, C Mordel, G Silipo, M Lichtenstein. Arch Gen Psychiatry 1999
357
17

A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients.
Donald C Goff, Lawrence Herz, Thomas Posever, Vivian Shih, Guochuan Tsai, David C Henderson, Oliver Freudenreich, A Eden Evins, Iftah Yovel, Hui Zhang,[...]. Psychopharmacology (Berl) 2005
87
18

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
Uriel Heresco-Levy, Marina Ermilov, Jonathan Shimoni, Baruch Shapira, Gail Silipo, Daniel C Javitt. Am J Psychiatry 2002
148
16

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Hsien-Yuan Lane, Yue-Cune Chang, Yi-Ching Liu, Chih-Chiang Chiu, Guochuan E Tsai. Arch Gen Psychiatry 2005
210
16

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Uriel Heresco-Levy, Daniel C Javitt, Richard Ebstein, Agnes Vass, Pesach Lichtenberg, Gali Bar, Sara Catinari, Marina Ermilov. Biol Psychiatry 2005
268
16

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.
Uriel Heresco-Levy, Marina Ermilov, Pesah Lichtenberg, Gali Bar, Daniel C Javitt. Biol Psychiatry 2004
174
16

The NIMH-MATRICS consensus statement on negative symptoms.
Brian Kirkpatrick, Wayne S Fenton, William T Carpenter, Stephen R Marder. Schizophr Bull 2006
790
16

Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
16

Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study.
Deepak C D'Souza, Rajiv Radhakrishnan, Edward Perry, Savita Bhakta, Nagendra M Singh, Richa Yadav, Danielle Abi-Saab, Brian Pittman, Santosh K Chaturvedi, Mahendra P Sharma,[...]. Neuropsychopharmacology 2013
51
29

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Guochuan Tsai, Hsien-Yuan Lane, Pinchen Yang, Mian-Yoon Chong, Nicholas Lange. Biol Psychiatry 2004
261
15

High dose D-serine in the treatment of schizophrenia.
Joshua T Kantrowitz, Anil K Malhotra, Barbara Cornblatt, Gail Silipo, Andrea Balla, Raymond F Suckow, Cyril D'Souza, John Saksa, Scott W Woods, Daniel C Javitt. Schizophr Res 2010
159
14

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
U Heresco-Levy, D C Javitt, M Ermilov, C Mordel, A Horowitz, D Kelly. Br J Psychiatry 1996
199
14


A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.
Hsien-Yuan Lane, Ching-Hua Lin, Yu-Jhen Huang, Chun-Hui Liao, Yue-Cune Chang, Guochuan E Tsai. Int J Neuropsychopharmacol 2010
126
13

Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials.
Paolo Fusar-Poli, Evangelos Papanastasiou, Daniel Stahl, Matteo Rocchetti, William Carpenter, Sukhwinder Shergill, Philip McGuire. Schizophr Bull 2015
321
13

Adjunctive high-dose glycine in the treatment of schizophrenia.
D C Javitt, G Silipo, A Cienfuegos, A M Shelley, N Bark, M Park, J P Lindenmayer, R Suckow, S R Zukin. Int J Neuropsychopharmacol 2001
124
12

The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation.
Ann M Kring, Raquel E Gur, Jack J Blanchard, William P Horan, Steven P Reise. Am J Psychiatry 2013
393
12

Amelioration of negative symptoms in schizophrenia by glycine.
D C Javitt, I Zylberman, S R Zukin, U Heresco-Levy, J P Lindenmayer. Am J Psychiatry 1994
287
12

D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial.
Joshua T Kantrowitz, Scott W Woods, Eva Petkova, Barbara Cornblatt, Cheryl M Corcoran, Huaihou Chen, Gail Silipo, Daniel C Javitt. Lancet Psychiatry 2015
93
12

D-serine added to clozapine for the treatment of schizophrenia.
G E Tsai, P Yang, L C Chung, I C Tsai, C W Tsai, J T Coyle. Am J Psychiatry 1999
166
12

D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
B N van Berckel, C N Evenblij, B J van Loon, M F Maas, M A van der Geld, H J Wynne, J M van Ree, R S Kahn. Neuropsychopharmacology 1999
63
17

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
Hsien-Yuan Lane, Chieh-Liang Huang, Po-Lun Wu, Yi-Ching Liu, Yue-Cune Chang, Pao-Yen Lin, Po-Wei Chen, Guochuan Tsai. Biol Psychiatry 2006
118
11

A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia.
Jeffrey A Lieberman, Kelly Papadakis, John Csernansky, Robert Litman, Jan Volavka, Xinwei Daniel Jia, Allyson Gage. Neuropsychopharmacology 2009
94
11

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
Richard S E Keefe, Herbert A Meltzer, Nancy Dgetluck, Maria Gawryl, Gerhard Koenig, Hans J Moebius, Ilise Lombardo, Dana C Hilt. Neuropsychopharmacology 2015
92
11

Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.
Y Iwata, S Nakajima, T Suzuki, R S E Keefe, E Plitman, J K Chung, F Caravaggio, M Mimura, A Graff-Guerrero, H Uchida. Mol Psychiatry 2015
64
17


Placebo-controlled trial of glycine added to clozapine in schizophrenia.
A E Evins, S M Fitzgerald, L Wine, R Rosselli, D C Goff. Am J Psychiatry 2000
129
11

Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
Chun-Yuan Lin, Sun-Yuan Liang, Yue-Cune Chang, Shuo-Yen Ting, Ching-Ling Kao, Yu-Hsin Wu, Guochuan E Tsai, Hsien-Yuan Lane. World J Biol Psychiatry 2017
52
21


Glycine binding primes NMDA receptor internalization.
Yi Nong, Yue-Qiao Huang, William Ju, Lorraine V Kalia, Gholamreza Ahmadian, Yu Tian Wang, Michael W Salter. Nature 2003
321
10


D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia.
Jennifer D Gottlieb, Corinne Cather, Meghan Shanahan, Timothy Creedon, Eric A Macklin, Donald C Goff. Schizophr Res 2011
53
18

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
791
10

Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
David de Lucena, Brisa Simões Fernandes, Michael Berk, Seetal Dodd, Dalton W Medeiros, Mariana Pedrini, Mauricio Kunz, Fabiano Alves Gomes, Larriany F Giglio, Maria Inês Lobato,[...]. J Clin Psychiatry 2009
81
12


Initial phase 2 trial of a nicotinic agonist in schizophrenia.
Robert Freedman, Ann Olincy, Robert W Buchanan, Josette G Harris, James M Gold, Lynn Johnson, Diana Allensworth, Alejandrina Guzman-Bonilla, Bettye Clement, M Patricia Ball,[...]. Am J Psychiatry 2008
335
10


Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
Joshua T Kantrowitz, Michael L Epstein, Migyung Lee, Nayla Lehrfeld, Karen A Nolan, Constance Shope, Eva Petkova, Gail Silipo, Daniel C Javitt. Schizophr Res 2018
55
18

Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
Oliver D Howes, Rob McCutcheon, Ofer Agid, Andrea de Bartolomeis, Nico J M van Beveren, Michael L Birnbaum, Michael A P Bloomfield, Rodrigo A Bressan, Robert W Buchanan, William T Carpenter,[...]. Am J Psychiatry 2017
387
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.